SPHS - Sophiris Bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.6811
-0.0262 (-3.70%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.7073
Open0.7073
Bid0.0000 x 900
Ask0.9015 x 27000
Day's Range0.6508 - 0.7104
52 Week Range0.6500 - 2.9500
Volume280,614
Avg. Volume146,725
Market Cap24.213M
Beta (3Y Monthly)3.07
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research

    SPHS: Awaiting Feedback from FDA on Phase 3 Plan for Topsalysin in Prostate Cancer…

    Sophiris Bio Inc. (SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland. The compound showed a 27% response rate in a Phase 2b clinical trial in patients with localized clinically significant prostate cancer and Sophiris is currently preparing for a Phase 3 clinical trial.

  • Zacks Small Cap Research

    SPHS: Details of Phase 3 Prostate Cancer Trial Based on Positive EMA Feedback…

    Sophiris Bio Inc. (SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland. The compound showed a 27% response rate in a Phase 2b clinical trial in patients with localized clinically significant prostate cancer and Sophiris is currently preparing for a Phase 3 clinical trial.

  • Some Sophiris Bio (FRA:BFF1) Shareholders Have Taken A Painful 79% Share Price Drop
    Simply Wall St.

    Some Sophiris Bio (FRA:BFF1) Shareholders Have Taken A Painful 79% Share Price Drop

    Even the best investor on earth makes unsuccessful investments. But it's not unreasonable to try to avoid truly...

  • Zacks Small Cap Research

    SPHS: EMA Guidance on Phase 3 Clinical Trial for Topsalysin Expected in 2Q19…

    Sophiris Bio Inc. (SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland. The compound showed a 27% response rate in a Phase 2b clinical trial in patients with localized clinically significant prostate cancer and Sophiris is currently preparing for a Phase 3 clinical trial.

  • Zacks Small Cap Research

    SPHS: Awaiting Regulatory Guidance for Topsalysin Phase 3 Study…

    Sophiris Bio Inc. (SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland. The compound showed a 27% response rate in a Phase 2b clinical trial in patients with localized clinically significant prostate cancer and Sophiris is currently preparing for a Phase 3 clinical trial.

  • Zacks Small Cap Research

    SPHS: Ready to Move Topsalysin into Phase 3 for Localized Clinically Significant Prostate Cancer…

    A total of 38 patients received a single administration of topsalysin to treat a clinically significant tumor, which was defined for this study as either a Gleason score of 6 (pattern 3 + 3) and greater than or equal to 6 mm maximum cancer core length (MMCL), or a Gleason score of 7 (pattern 3 + 4) and less than or equal to 10 mm MCCL. Ten patients received a second administration of topsalysin due to having a partial response to the first treatment, however their lesions were still clinically significant.

  • Does Sophiris Bio Inc (FRA:BFF1) Have A Volatile Share Price?
    Simply Wall St.

    Does Sophiris Bio Inc (FRA:BFF1) Have A Volatile Share Price?

    If you own shares in Sophiris Bio Inc (FRA:BFF1) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...

  • Zacks Small Cap Research

    SPHS: Data from Second Administration of Topsalysin in Phase 2b Trial Anticipated Before End of 2018…

    By David Bautz, PhD NASDAQ:SPHS READ THE FULL SPHS RESEARCH REPORT Business Update Interim Safety and Efficacy Data for Phase 2b Trial of Topsalysin in Localized Prostate Cancer Earlier in 2018, Sophiris ...